Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen (Q28477151)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen	scientific article

Statements

scholarly article

0 references

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

Marie-Laure Chaix

9

0 references

Christine Rouzioux

8

0 references

Jean-François Delfraissy

7

object named as

Jean-François Delfraissy

0 references

Philippe Flandre

object named as

Philippe Flandre

3

0 references

Constance Delaugerre

2

object named as

Constance Delaugerre

0 references

1

object named as

Jade Ghosn

0 references

4

object named as

Julie Galimand

0 references

Isabelle Cohen-Codar

5

object named as

Isabelle Cohen-Codar

0 references

François Raffi

6

object named as

François Raffi

0 references

language of work or name

0 references

publication date

2011

0 references

0 references

6

0 references

e24798

0 references

9

0 references

copyright license

Creative Commons Attribution 4.0 International

20 September 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

19 March 2017

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

7 April 2017

Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

29 September 2017

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

2 June 2018

Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

2 June 2018

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

2 June 2018

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

2 June 2018

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibit

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Differential stability of the mRNA secondary structures in the frameshift site of various HIV type 1 viruses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0024798

21 January 2018

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

27 November 2018

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176769

27 November 2018

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21949754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21949754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0024798

0 references

2011PLoSO...624798G

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28477151&oldid=1868818709"